7V0.XETRA Novogenia AG

Healthcare Biotechnology XETRA Stock Exchange
6.50 EUR
Close of Nov 6, 2026
5.55 11.01
Market cap
EUR 78.0M
P/E
130.0x
P/B
0.78x
ROE
0.5%
Dividend yield
4.59%
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 7V0.XETRA undervalued?

Graham number
Price6.50
Graham value3.06
Premium112.1%

7V0.XETRA trades 112.1% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Novogenia AG fundamental analysis

No fundamental analysis for Novogenia AG yet.

Novogenia AG stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Novogenia AG

Novogenia AG manufactures and sells personalized health products in global markets. The company offers products, such as personalized supplements and cosmetics; and services, including genetic testing, advanced therapies like personalized infusion therapies and reproductive genetics, and contract manufacturing. The company was formerly known as Darwin AG and changed its name to Novogenia AG in June 2026. The company was incorporated in 2021 and is based in Munich, Germany.

Full company profile